Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension of Asenapine in Schizophrenia
NCT01142596Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- May 2010
- Primary completion
- Apr 2015
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of asenapine in schizophrenia (2 arms), sponsored by Organon & Co. Primary endpoints: Percentage of Participants in Categories of Change in Weight From Study P06124 Baseline to Final Assessment at Week 52, Change From Study P06124 Baseline in Body Mass Index (BMI) at Week 52 and 10 more. Started May 2010; status: completed.
02
Drugs
asenapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01142596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01142596.